ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous systemic treatment and have exhausted other available treatment options.
With this approval, ENHERTU achieves a groundbreaking milestone as the premier therapy targeting HER2 across various tumor types, marking the first ADC to secure such a broad indication. ENHERTU, an ADC targeting HER2, was developed by Daiichi Sankyo and is currently undergoing joint d...
